The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Outcomes of limited stage peripheral T-cell lymphoma
Ahmed Ludvigsen Al-Mashhadi
• 21 Jun 2020
Ahmed Ludvigsen Al-Mashhadi, MD, of the Aalborg University Hospital, Aalborg, Denmark, discusses a study presented by the NORDIC lymphoma group in limited stage peripheral T-cell lymphoma patients after CHOP-like therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
